Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 4, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

April 16, 2021

Conditions
Newly Diagnosed High-Grade Glioma
Interventions
DRUG

Mebendazole

The mebendazole will be given by mouth three times every day on a 28 day cycle. it's in the form of 500 mg chewable tablets, to be taken with meals.

Trial Locations (1)

21287

The Johs Hopkins Hospital, Baltimore

All Listed Sponsors
collaborator

Accelerate Brain Cancer Cure

OTHER

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01729260 - Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide | Biotech Hunter | Biotech Hunter